Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Sponsor: Janssen Research & Development, LLC
Summary
The main purpose of this study is to assess how well the study drug (JNJ-42847922) works (efficacy) compared with placebo in improving depressive symptoms in participants with major depressive disorder (\[MDD\], a common mood disorder that causes a lasting feeling of sadness and a loss of interest in everyday activities) in double-blind treatment phase. Further, to evaluate long-term safety and tolerability of JNJ-42847922 in participants with MDD in the open label treatment phase.
Official title: A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment With Seltorexant
Key Details
Gender
All
Age Range
18 Years - 74 Years
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2026-04-30
Completion Date
2029-05-03
Last Updated
2026-05-08
Healthy Volunteers
No
Conditions
Interventions
Seltorexant
Seltorexant tablet will be administered orally.
Placebo
Placebo tablet will be administered orally.
Locations (5)
UHC Research
Doral, Florida, United States
Nuovida Research Center
Miami, Florida, United States
Accelerated Clinical Research Group LLC
Snellville, Georgia, United States
Patient Priority Clinical Sites LLC
Cincinnati, Ohio, United States
Northwest Clinical Research Center
Bellevue, Washington, United States